We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+43%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$926M
AUM Growth
+$212M
Cap. Flow
-$7.45M
Cap. Flow %
-0.8%
Top 10 Hldgs %
29.66%
Holding
99
New
14
Increased
24
Reduced
46
Closed
5

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$17.6M
2
BAX icon
Baxter International
BAX
+$8.28M
3
XLRN
Acceleron Pharma
XLRN
+$8.19M
4
UNH icon
UnitedHealth
UNH
+$7.16M
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.1M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$10.7M
2
ESPR
Esperion Therapeutics
ESPR
+$7.02M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$6.08M
4
NKTR icon
Nektar Therapeutics
NKTR
+$5.93M
5
MGNX icon
MacroGenics
MGNX
+$5.65M

Sector Composition

Rank Sector Weight
1 Healthcare 94.86%
2 Communication Services 1.03%
3 Energy 0.07%
4 Technology 0.06%
5 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TMO icon
51
Thermo Fisher Scientific
TMO
$222B
$6.88M 0.74%
19,000
– –
ZBH icon
52
Zimmer Biomet
ZBH
$18.7B
$6.8M 0.74%
58,710
-23,690
-29% -$2.73M
BLUE
53
DELISTED
bluebird bio
BLUE
$6.58M 0.71%
8,322
+3,150
+61% +$2.38M
SGMO
54
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$6.05M 0.65%
675,000
-25,000
-4% -$232K
ALKS icon
55
Alkermes
ALKS
$8.29B
$6.02M 0.65%
310,000
-89,000
-22% -$1.44M
KYNB
56
Kyntra Bio
KYNB
$28.2M
$5.88M 0.63%
5,800
-4,200
-42% -$3.9M
SILK
57
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$5.87M 0.63%
140,000
-35,000
-20% -$1.34M
APLS
58
DELISTED
Apellis Pharmaceuticals
APLS
$5.39M 0.58%
165,000
+65,000
+65% +$2.09M
GKOS icon
59
Glaukos
GKOS
$10.7B
$5.38M 0.58%
140,000
-25,000
-15% -$931K
RVNC
60
DELISTED
Revance Therapeutics, Inc.
RVNC
$5.37M 0.58%
220,000
– –
BDX icon
61
Becton Dickinson
BDX
$48.9B
$5.03M 0.54%
21,525
+7,175
+50% +$1.73M
AGIO icon
62
Agios Pharmaceuticals
AGIO
$1.95B
$4.81M 0.52%
90,000
-20,000
-18% -$926K
RARE icon
63
Ultragenyx Pharmaceutical
RARE
$2.64B
$4.81M 0.52%
61,500
-7,024
-10% -$465K
AIMT
64
DELISTED
Aimmune Therapeutics
AIMT
$4.76M 0.51%
285,000
+120,000
+73% +$2.04M
GTHX
65
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$4.61M 0.5%
190,000
-60,172
-24% -$995K
BIIB icon
66
Biogen
BIIB
$30.6B
$4.55M 0.49%
17,000
-8,000
-32% -$2.4M
RDUS
67
DELISTED
Radius Health, Inc.
RDUS
$4.52M 0.49%
331,826
+36,826
+12% +$507K
EPZM
68
DELISTED
Epizyme, Inc
EPZM
$4.26M 0.46%
265,000
-85,000
-24% -$1.48M
OMCL icon
69
Omnicell
OMCL
$1.7B
$4.24M 0.46%
60,000
-26,095
-30% -$1.79M
INCY icon
70
Incyte
INCY
$24.6B
$4.16M 0.45%
40,000
-10,000
-20% -$964K
MNTA
71
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$3.99M 0.43%
120,000
-1,400
-1% -$44.6K
MGTX icon
72
MeiraGTx Holdings
MGTX
$1.21B
$3.76M 0.41%
300,000
+53,693
+22% +$748K
AMRN
73
Amarin Corp
AMRN
$298M
$3.63M 0.39%
26,250
-1,250
-5% -$172K
RIGL icon
74
Rigel Pharmaceuticals
RIGL
$778M
$3.18M 0.34%
173,618
– –
MYOV
75
DELISTED
Myovant Sciences Ltd.
MYOV
$3.09M 0.33%
+150,000
New +$2.04M
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2020 Portfolio in Review

As of Q2 2020, Rhenman & Partners Asset Management held 99 positions worth $926M, up 30% from $714M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management's Q2 2020 filing shows 14 new, 24 increased, 46 reduced and 5 closed positions. Its largest new stake was Gilead Sciences: 230,000 shares worth $17.7M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 96% a quarter earlier, followed by Communication Services and Energy.

  • Rhenman & Partners Asset Management's largest Q2 2020 buy was Gilead Sciences: 230,000 shares worth $17.7M.
  • Rhenman & Partners Asset Management added most to Acceleron Pharma in Q2 2020, an estimated $8.19M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2020 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $10.7M.
  • Rhenman & Partners Asset Management fully exited Stemline Therapeutics, Inc. in Q2 2020, selling an estimated $3.15M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $926M portfolio in Q2 2020.
  • Rhenman & Partners Asset Management opened 14 new positions and closed 5 in Q2 2020.
  • Rhenman & Partners Asset Management's portfolio value rose 30% quarter-over-quarter to $926M.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2020, filed 16 Jul 2020.